Skip to content
‹ Back to IndustriesSciences

Japan’s Radioactive Water Release Won’t Impact Neighboring Countries, Despite China’s Opposition and Ban on Japanese Seafood

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima. However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Alexandra Simon · · ChinaFukushimaJapanRadioactive Release
Share

Key takeaways

01

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima.

02

However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima. However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive waste responsibilities. 

It’s easy to get caught in the emotion and politics of the situation, especially when it involves terms like “radioactive release,” but understanding the science and safety protocols is crucial. Independent organizations like the International Atomic Energy Agency (IAEA) provide not just oversight but also expertise in making sure that any release is carried out to stringent safety standards. For instance, the tritium levels being released from Fukushima meet standards set by the World Health Organization and the Japanese government. The release of tritiated water is a monitored, understood, and internationally sanctioned activity that comes as a part of the territory with nuclear energy. 

To further explain the safety of this effort and how public perception impacts nuclear outlook is Ken Petersen, President of the American Nuclear Society. He brings years of experience and knowledge on the subject. Previously he was the vice president for nuclear fuels at Exelon Generation Company (EGC) for more than 12 years. He even worked on a contract with the U.S. Department of Energy, and has a Bachelor’s and Master’s in nuclear engineering from the University of Wisconsin.

Petersen mentioned that Japan’s release of tritiated water — water that’s been heavily treated, undergoes safety protocols set by global standards. He further added that China’s opposition bears hypocrisy given that they, too, have also released radioactive water under those same guidelines.

Petersen’s Thoughts on Radioactive Water Release

“Sure. So, I mean, the site is no longer has room for expanded storage. So, something has to happen with the tritiated water. It’s been, you know, filtered twice and, you know, what is remaining is a little bit of tritium that’s going to be blended down even further and released. So, it’s going to be monitored and released. The IAEA has reviewed it. They will have somebody there monitoring it to assure that everything is done appropriately. So, this is no different than any other plant. 

“So, when you have a radioactive release, it is monitored and it meets the criteria. And it’s, you know, one-seventh of the World Health Organization levels. And it’s a fortieth of what the Japanese government limits are. So, it’s a very understood and very small amount. Well, there’s a history from their neighbors where, you know, some of their neighbors don’t get along very well. But the neighbors who are speaking loudly also have reactors where they’ll do the exact same thing. You know, they will have tritium releases. They will be monitored and be well within safety levels. Yeah, this shouldn’t impact that at all. So, this is a very unfortunate situation, you know, that the Fukushima plants had the earthquake and following tsunami. And it resulted with this large storage of tritiated water and it is just a monitored release. It should have no impact on the outlook for new nuclear.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

AS
Alexandra SimonFreelance Writer

Alexandra is a freelance writer based in New York City. She's a big fan of true crime television and the Oxford comma. She has a background in local news reporting, beat reporting, magazine writing, SEO writing, and copywriting.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz's AAV2 gene therapy for retinitis pigmentosa, through IND-enabling work and a planned Phase 1/2 trial. CLZ002 targets retinal repair, not mutations. Because the disease is linked to more than 90 genes, one manufacturing process could end up serving a broad patient group.

  • 01Retinitis pigmentosa has more than 90 causal genes; CLZ002 aims at a shared retinal repair pathway, so a single AAV2 manufacturing process would serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab Manager survey finds 2027 lab hiring budgets nearly flat while supply budgets grow

Lab hiring budgets for 2027 carry a net outlook of just +2, down from +10, while consumables sit at +30 and raw materials at +31. Labs are paying for supplies and planning capital purchases further ahead. New positions face the toughest scrutiny.

  • 01Labs heading into 2027 expect their reagent budgets to grow and their headcount budgets to stall: consumables carry a net outlook of +30, hiring just +2.
  • 02Lab Manager’s read: if consumables spending stays flat, the lab is probably buying less—because respondents reported rising costs across many supply items, from reagents to shipping.
  • 03Hiring gets treated as a recurring cost, not a one-time purchase; one published example estimates ~$46,000/year for a graduate student and $80,000–$100,000 for a postdoc (with fringe) at one institution. Lab Manager recommends justifying new roles with throughput, turnaround and risk—while separating price from volume in supply-line requests.

Nov 13, 2026

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra opens $250 million-plus Bloomington building with three sterile filling lines

Simtra BioPharma Solutions opened Building H, a $250 million-plus addition to its Bloomington, Indiana campus, featuring two syringe lines and a vial line with lyophilizers. The CDMO plans to expand from 11 to 18 filling lines by 2027. Extra sites reduce supply risk only when products are qualified at both locations.

  • 01Simtra's network is set to grow from 11 to 18 filling lines across Indiana and Germany by 2027, a published capacity timeline sponsors can plan tech transfers against.
  • 02A second fill site cuts supply risk only after a product has been validated there; for biologics that means process validation, comparability work and regulatory filings first.
  • 03Programs whose real exposure sits in concentrated starting-material supply gain little from added fill-finish redundancy, however well the new lines are built.

Nov 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

AS
Alexandra Simon

Freelance Writer

Alexandra is a freelance writer based in New York City. She's a big fan of true crime television and the Oxford comma. She has a background in local news reporting, beat reporting, magazine writing, SEO writing, and copywriting.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512